Results 161 to 170 of about 31,601 (273)

Regional management of biosimilars in Germany [PDF]

, 2016
Mathias Flume
openalex   +1 more source

Creating China’s Biosimilar Drugs Regulatory System: A Calculated Approach [PDF]

, 2022
Jianhong Yang, Xiaoyu Zhao, Jie Li, Kejian Zhang, Zheru Zhang, Shunwen Chang, Daotian Fu, Xinhuan Lyu, Xianglin Zhang, Ying Shao   +9 more
openalex   +1 more source

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

Open Access Rheumatology: Research and Reviews, 2017
Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway ...
Abdalla A, Byrne N, Conway R, Walsh T, Mannion G, Hanly M, O'Sullivan M, Curran AM, Carey JJ   +8 more
doaj  

Efficacy and Safety of Folisurge, a Biosimilar Recombinant Follicle-Stimulating Hormone, Versus Gonal-F in Assisted Reproductive Technology Practice in India: A Real-World Study [PDF]

Shashank Sanagoudar, V Chandra, Shipra Nigam, Anjali Gahalan, Ritu Punhani, Nihita Pandey, Sara Zaidi, J. Panday, Nihar Ranjan Bhoi, Walmik Mistari, Isha Suwalka, Nitasha Gupta   +11 more
openalex   +1 more source

Biosimilars: Patient Perspectives, Challenges and Emerging Solutions: Current Opinions [PDF]

, 2019
Frapaise FX
openalex   +1 more source

G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: A French, multicenter, prospective, non-interventional study

, 2023
Jean–Marc Phelip, Pierre-Jean Souquet, Maya Hacini, Mohamad Chehimi, Vincent Bourgeois, Ryma Bennoune, Olivier Trédan   +6 more
openalex   +1 more source

Generics, Biosimilars, and the Ethics of Pricing Pharmaceuticals [PDF]

, 2016
Mark A. Brown
openalex   +1 more source

Sandoz Inc. v. Amgen Inc.: Removing Barriers to Market Access for Biosimilar Manufacturers [PDF]

, 2019
Koya, Moyosore O.
core   +1 more source

A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC

, 2019
Martin Reck, Alexander Luft, Igor Bondarenko, Serhii Shevnia, Dmytro Trukhin, Н. В. Коваленко, K Vacharadze, Freschi Andrea, A. O. Hontsa, Jeong‐Yoon Choi, D.B. Shin   +10 more
openalex   +1 more source

The economic pressures for biosimilar drug use in cancer medicine [PDF]

, 2012
Paul Cornes
openalex   +1 more source